Cassava Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cassava Sciences, Inc.
The company completed a $170m series D round and plans to start trials combining the drug with GLP-1 agonists like Eli Lilly’s Zepbound in mid-2024.
Zydus MD Sharvil Patel talks to Scrip about a pipeline-in-a-drug approach for novel molecules like ZYIL-1, the intent behind deals with Daewoong and LiqMeds and expected timelines for trial readouts of its PBC/NASH candidate saroglitazar
Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.
To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.
- Other Names / Subsidiaries
- Pain Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.